Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05921760 |
| Title | Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | Yes |
| Sponsors | Servier Bio-Innovation LLC |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | GBR |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| UCSF - Medical Center at Mission Bay | San Francisco | California | 94158 | United States | Details | |
| Ucsf Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94158 | United States | Details | |
| Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins | Baltimore | Maryland | 21231 | United States | Details | |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | United States | Details | |
| UCLH | London | NW1 2PG | United Kingdom | Details |